BDBM50244264 CHEMBL471979::trans-4-(((4-tert-butylcyclohexyl)(6-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)amino)methyl)-N-(1H-tetrazol-5-yl)benzamide

SMILES: COc1ccc2nc(N(Cc3ccc(cc3)C(=O)Nc3nnn[nH]3)[C@H]3CC[C@@H](CC3)C(C)(C)C)n(C)c2c1

InChI Key: InChIKey=ITADOTUWBBIWST-MEMLXQNLSA-N

Data: 3 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 50244264   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Glucagon receptor (Homo sapiens (Human))	BDBM50244264 (CHEMBL471979 | trans-4-(((4-tert-butylcyclohexyl)(...) Show SMILES COc1ccc2nc(N(Cc3ccc(cc3)C(=O)Nc3nnn[nH]3)[C@H]3CC[C@@H](CC3)C(C)(C)C)n(C)c2c1 |r,wU:24.25,wD:27.32,(11.41,-44.22,;12.15,-45.57,;13.69,-45.6,;14.49,-44.28,;16.03,-44.32,;16.76,-45.67,;18.26,-46.03,;18.38,-47.56,;19.72,-48.34,;19.71,-49.88,;21.04,-50.66,;22.37,-49.89,;23.7,-50.67,;23.69,-52.21,;22.34,-52.97,;21.02,-52.19,;25.02,-52.99,;25.01,-54.53,;26.36,-52.23,;27.69,-53.01,;28.2,-54.45,;29.74,-54.42,;30.18,-52.94,;28.91,-52.07,;21.04,-47.58,;21.05,-46.04,;22.39,-45.28,;23.72,-46.06,;23.71,-47.61,;22.37,-48.36,;25.06,-45.31,;26.39,-44.53,;25.84,-46.64,;24.3,-43.97,;16.96,-48.16,;16.19,-49.49,;15.96,-46.98,;14.43,-46.95,)| Show InChI InChI=1S/C28H36N8O2/c1-28(2,3)20-10-12-21(13-11-20)36(27-29-23-15-14-22(38-5)16-24(23)35(27)4)17-18-6-8-19(9-7-18)25(37)30-26-31-33-34-32-26/h6-9,14-16,20-21H,10-13,17H2,1-5H3,(H2,30,31,32,33,34,37)/t20-,21-	PDB MMDB UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	213	n/a	n/a	n/a	n/a	n/a	n/a
Merck Research Laboratories Curated by ChEMBL					Assay Description Antagonist activity against human GCGR expressed in CHO cells assessed as glucagon-induced cAMP accumulation				Bioorg Med Chem Lett 18: 3701-5 (2008) Article DOI: 10.1016/j.bmcl.2008.05.072 BindingDB Entry DOI: 10.7270/Q26Q1X25
					More data for this Ligand-Target Pair
Glucagon receptor (Homo sapiens (Human))	BDBM50244264 (CHEMBL471979 | trans-4-(((4-tert-butylcyclohexyl)(...) Show SMILES COc1ccc2nc(N(Cc3ccc(cc3)C(=O)Nc3nnn[nH]3)[C@H]3CC[C@@H](CC3)C(C)(C)C)n(C)c2c1 |r,wU:24.25,wD:27.32,(11.41,-44.22,;12.15,-45.57,;13.69,-45.6,;14.49,-44.28,;16.03,-44.32,;16.76,-45.67,;18.26,-46.03,;18.38,-47.56,;19.72,-48.34,;19.71,-49.88,;21.04,-50.66,;22.37,-49.89,;23.7,-50.67,;23.69,-52.21,;22.34,-52.97,;21.02,-52.19,;25.02,-52.99,;25.01,-54.53,;26.36,-52.23,;27.69,-53.01,;28.2,-54.45,;29.74,-54.42,;30.18,-52.94,;28.91,-52.07,;21.04,-47.58,;21.05,-46.04,;22.39,-45.28,;23.72,-46.06,;23.71,-47.61,;22.37,-48.36,;25.06,-45.31,;26.39,-44.53,;25.84,-46.64,;24.3,-43.97,;16.96,-48.16,;16.19,-49.49,;15.96,-46.98,;14.43,-46.95,)| Show InChI InChI=1S/C28H36N8O2/c1-28(2,3)20-10-12-21(13-11-20)36(27-29-23-15-14-22(38-5)16-24(23)35(27)4)17-18-6-8-19(9-7-18)25(37)30-26-31-33-34-32-26/h6-9,14-16,20-21H,10-13,17H2,1-5H3,(H2,30,31,32,33,34,37)/t20-,21-	PDB MMDB UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	4	n/a	n/a	n/a	n/a	n/a	n/a
Merck Research Laboratories Curated by ChEMBL					Assay Description Displacement of [125I]glucagon from human GCGR expressed in CHO cells				Bioorg Med Chem Lett 18: 3701-5 (2008) Article DOI: 10.1016/j.bmcl.2008.05.072 BindingDB Entry DOI: 10.7270/Q26Q1X25
					More data for this Ligand-Target Pair
Gastric inhibitory polypeptide (Homo sapiens (Human))	BDBM50244264 (CHEMBL471979 | trans-4-(((4-tert-butylcyclohexyl)(...) Show SMILES COc1ccc2nc(N(Cc3ccc(cc3)C(=O)Nc3nnn[nH]3)[C@H]3CC[C@@H](CC3)C(C)(C)C)n(C)c2c1 |r,wU:24.25,wD:27.32,(11.41,-44.22,;12.15,-45.57,;13.69,-45.6,;14.49,-44.28,;16.03,-44.32,;16.76,-45.67,;18.26,-46.03,;18.38,-47.56,;19.72,-48.34,;19.71,-49.88,;21.04,-50.66,;22.37,-49.89,;23.7,-50.67,;23.69,-52.21,;22.34,-52.97,;21.02,-52.19,;25.02,-52.99,;25.01,-54.53,;26.36,-52.23,;27.69,-53.01,;28.2,-54.45,;29.74,-54.42,;30.18,-52.94,;28.91,-52.07,;21.04,-47.58,;21.05,-46.04,;22.39,-45.28,;23.72,-46.06,;23.71,-47.61,;22.37,-48.36,;25.06,-45.31,;26.39,-44.53,;25.84,-46.64,;24.3,-43.97,;16.96,-48.16,;16.19,-49.49,;15.96,-46.98,;14.43,-46.95,)| Show InChI InChI=1S/C28H36N8O2/c1-28(2,3)20-10-12-21(13-11-20)36(27-29-23-15-14-22(38-5)16-24(23)35(27)4)17-18-6-8-19(9-7-18)25(37)30-26-31-33-34-32-26/h6-9,14-16,20-21H,10-13,17H2,1-5H3,(H2,30,31,32,33,34,37)/t20-,21-	PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	>1.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Merck Research Laboratories Curated by ChEMBL					Assay Description Binding affinity against human GIP				Bioorg Med Chem Lett 18: 3701-5 (2008) Article DOI: 10.1016/j.bmcl.2008.05.072 BindingDB Entry DOI: 10.7270/Q26Q1X25
					More data for this Ligand-Target Pair